Biotech · Private company
Allotera Therapeutics
Track this companyFree. Adds Allotera Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials73 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- WU-CART-007Phase 2 · T-cell Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Cetuximab - Cohort ExpansionPhase 1 · Colorectal Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- Cetuximab - Dose EscalationPhase 1 · Colorectal Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- WU-NK-101Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- WU-NK-101 - Cohort ExpansionPhase 1 · Colorectal Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- WU-NK-101 - Dose EscalationPhase 1 · Colorectal Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- Genetic: WU-CART-007T-cell Acute Lymphoblastic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)PHASE2 · RECRUITING · started Jan 31, 2025ClinicalTrials.gov NCT06514794 · fetched Nov 12, 2026
- A Phase 1b Study of WU-NK-101 in Combination With CetuximabPHASE1 · ACTIVE_NOT_RECRUITING · started May 21, 2024ClinicalTrials.gov NCT05674526 · fetched Nov 12, 2026
- Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesPHASE1 · SUSPENDED · started Oct 10, 2023ClinicalTrials.gov NCT05377827 · fetched Nov 12, 2026
- A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)PHASE1 · COMPLETED · started Jul 1, 2023ClinicalTrials.gov NCT05470140 · fetched Nov 12, 2026
- A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007ENROLLING_BY_INVITATION · started Aug 22, 2022ClinicalTrials.gov NCT05509855 · fetched Nov 12, 2026
- A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBLPHASE1 · COMPLETED · started Jan 14, 2022ClinicalTrials.gov NCT04984356 · fetched Nov 12, 2026
- Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell TransplantPHASE1_PHASE2 · COMPLETED · started Oct 23, 2017ClinicalTrials.gov NCT03068819 · fetched Nov 12, 2026